LOCAL THERAPY FOR UROGENITAL DISORDERS COMPLICATED BY IMPAIRED URINATION AND PELVIC PAIN SYNDROME IN POSTMENOPAUSAL WOMEN

Objective. To determine the efficiency of combination therapy involving depantol for postmenopausal women with urogenital disorders. Subject and methods. Fifty women aged 42 to 62 years with urogenital disorders were followed up. Physical and bimanual vaginal examinations, vaginal pH determination, colposcopy, vaginal index scoring, urine and vaginal swab culture testing for flora, urinary diary keeping, complex urodynamic study, cystoscopy and laser Doppler flowmetry of the vaginal and bladder mucosae, and small pelvic ultrasound imaging were used in all the patients. The tests were repeated after termination of a 3-month course of therapy and 6 months after the patients being recruited into the trial. Two patient groups were identified. Control Group 1 comprised 20 patients who received etiotropic therapy for chronic cystitis. Group 2 was additionally given depantol as vaginal suppositories per day for 20 days. Results. In Group 1, the disease recurred in 50% of the patients; the clinical presentation of atrophic colpitis and cystourethritis continued or even worsened. Much better results were recorded in Group 2: 70% of the patients had no recurrent urogenital disorders, such as urination disorders, dyspareunia, vaginal dryness and burning, and profuse unpleasant vaginal discharges. Normal vaginal acidity (pH <5) was preserved; the signs of mucosal atrophy noticeably reduced. Group 2 patients receiving depantol showed a substantial microcirculatory improvement in the bladder and vagina mucosae by the end of drug administration. Conclusion. Depantol can effectively relieve the symptoms of urogenital disorders, resume or improve sexual life and eventually increase considerably quality of life in these women.

urogenital disorders, dysuresis, depantol, atrophic vulvovaginitis